Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Vaccine maker Moderna, Inc. (MRNA) said on Monday that its experimental seasonal flu vaccine demonstrated strong ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Used in very low amounts, thimerosal has been used since the 1930s to prevent contamination in multidose vaccine vials, and ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines in the US under new Health and Human Services (HHS) Secretary Robert F ...